Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 12/20 | 0.62 |
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18952532 | 0.89 | NPC1 (0.58) | S1PR4NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL18952542 | 0.82 | S1PR4 (0.50) | S1PR4NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL7011056 | 0.81 | NPC1 (0.67) | S1PR4NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL18952588 | 0.81 | S1PR4 (0.49) | S1PR4NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL18952619 | 0.79 | S1PR4 (0.42) | S1PR4NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4826271 | 0.77 | S1PR4 (0.42) | S1PR4NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL2135911 | 0.76 | S1PR4 (0.47) | S1PR4MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL187354 | 0.76 | NPC1 (0.64) | S1PR4NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL15616516 | 0.76 | KMT2A (0.55) | S1PR4NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL29397474 | 0.75 | S1PR4 (0.49) | S1PR4NPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386978-B1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| EP-3386978-B1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-20200291034-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200291034-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-10562903-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562903-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190010156-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-01-10 | — | — | US | disclosed |
| EP-3386978-A1 | BRIDGED PIPERIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-10-17 | — | — | EP | disclosed |
| CN-108137579-A | Bridging piperidine derivative | 豪夫迈·罗氏有限公司 | 2018-06-08 | — | — | CN | disclosed |
| WO-2017097728-A1 | BRIDGED PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017097728-A1 | BRIDGED PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291034-A1 | BRIDGED PIPERIDINE DERIVATIVES | PTGDR, HPGDS, PSEN1 | S1PR4 722/4885NPC1 440/4885RAB9A 1413/4885 |
| US-10562903-B2 | Bridged piperidine derivatives | PTGDR, HPGDS, PSEN1 | S1PR4 722/4885NPC1 440/4885RAB9A 1413/4885 |
| US-20190010156-A1 | BRIDGED PIPERIDINE DERIVATIVES | PTGDR, HPGDS, PSEN1 | S1PR4 722/4885NPC1 440/4885RAB9A 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.